Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25174282 | 0.89 | BACE1 (0.33) | USP30BACE1BACE2PRMT5WDR77 | |
| SCHEMBL30369811 | 0.89 | BACE1 (0.33) | USP30BACE1BACE2PRMT5WDR77 | |
| SCHEMBL17518584 | 0.85 | BACE1 (0.34) | AAK1USP30BACE1BACE2PRMT5 | |
| SCHEMBL29363705 | 0.85 | GPR119 (0.33) | — | |
| SCHEMBL25028818 | 0.85 | GPR119 (0.33) | — | |
| SCHEMBL19876637 | 0.84 | PTGDR2 (0.31) | — | |
| SCHEMBL12005659 | 0.83 | USP30 (0.35) | AAK1USP30PRMT5WDR77 | |
| SCHEMBL28594656 | 0.81 | HTR6 (0.40) | USP30BACE1BACE2PRMT5WDR77 | |
| SCHEMBL18270928 | 0.80 | USP30 (0.36) | USP30BACE1BACE2PRMT5WDR77 | |
| SCHEMBL16205575 | 0.79 | USP30 (0.33) | AAK1USP30PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185456-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185456-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION, APPLICATION METHODS AND USES THEREOF | POLRMT, EIF2AK2, POLM | AAK1 2208/4885USP30 1402/4885BACE1 2968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.